>

WEBINARS

RSS
>

MEETINGS / EVENTS

RSS
>

FDA MEDWATCH ALERTS

RSS

May 14, 2013

Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses

Summary:

Zolpidem Containing Products Drug Safety Communication

May 09, 2013

The Compounding Shop: FDA News Release - Lack of Sterility Assurance of Drug Products

Summary:

The Compounding Shop FDA News Release Lack of Sterility

May 08, 2013

Maquet SERVO-i Ventilator Battery Module: Class 1 Recall - Battery Run Time Shorter Than Expected

Summary:

Maquet SERVOi Ventilator Battery Module Class 1 Recall Battery Run Time Shorter Than Expected

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-13CE

... Read more »

Single Copies, Member Price: $360

Template 4

The World Health Organization (WHO) analgesic ladder consists of a hierarchy of oral pharmacologic interventions designed to effectively treat pain of increasing magnitude. The ladder presents a framework for the rational use of oral medication before application of other techniques of drug administration. Opioid therapy is considered the mainstay approach for patients with moderate or severe pain. The type of medication administered is sequentially escalated from nonopioids (e.g., nonsteroidal antiinflammatory drugs (NSAIDs) adjuvants to opioids used for mild to moderate pain (codeine, dihydrocodeine, oxycodone (compounded with a coanalgesic), hydrocodone, dihydrocodone) adjuvants to opioids commonly used for severe pain (morphine, hydromorphone, methadone, oxycodone (without compounding), fentanyl or levorphanol). Adjuvant medications are listed in template 7. (Modified with permission from WHO: Cancer pain relief and palliative care: Report of a WHO expert committee. Geneva, World Health Organization, 1990 (technical report series, no. 804).)